Kimberly Riemer
Acute Care · Boulder, CONPI 1902915630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,291 of the $7,003 with a category attached, or 89.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,076 and has fallen 52.2% since, to $992 in 2025. Among acute care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $29.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Medtronic$720
- Amgen$627
- Alnylam Pharmaceuticals Inc.$458
- Abiomed$416
- Boehringer Ingelheim$403
- plus $3K from 28 others
What the payments were for
- Travel & lodging$5999%
- Food & beverage$6,29190%
- Education$260%
- Other$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,061 |
| Medtronic | 8 | $720 |
| Amgen | 26 | $627 |
| Alnylam Pharmaceuticals Inc. | 17 | $458 |
| Abiomed | 4 | $416 |
| Boehringer Ingelheim | 15 | $403 |
| AstraZeneca | 18 | $376 |
| Johnson & Johnson | 16 | $318 |
| Pfizer | 16 | $286 |
| Merck | 14 | $245 |
| Esperion Therapeutics, Inc. | 13 | $241 |
| Novartis | 11 | $231 |
| Sanofi-aventis U.S. LLC | 8 | $207 |
| E.r. Squibb & Sons, L.L.C. | 9 | $189 |
| Baxter Healthcare | 3 | $138 |
| Edwards Lifesciences | 1 | $126 |
| Cardiovascular Systems Inc. | 1 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $110 |
| Heartflow, Inc. | 7 | $102 |
| Cvrx, Inc. | 3 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 3 | $58 |
| Novo Nordisk | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $53 |
| Abbott | 2 | $47 |
| Atricure, Inc. | 3 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Convatec Inc. | 1 | $27 |
| Bridgebio Pharma, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$908
- Impella$386
- HawkOne$176
- RESOLUTE ONYX$164
- Resolute$161
- JARDIANCE$124
- Diamondback Coronary$116
- Micra$106
How this compares
$7,003 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 292 | $328,811 |
| JardianceEmpagliflozin | 87 | $91,245 |
| XareltoRivaroxaban | 63 | $90,423 |
| Repatha SureclickEvolocumab | 40 | $44,590 |
| EntrestoSacubitril/Valsartan | 25 | $39,365 |
| Praluent PenAlirocumab | 24 | $13,976 |
| Metoprolol Succinate | 296 | $3,896 |
| Rosuvastatin Calcium | 249 | $3,319 |
| Atorvastatin Calcium | 261 | $2,353 |
| Flecainide Acetate | 75 | $2,127 |
| Pitavastatin Calcium | 12 | $2,062 |
| Valsartan | 64 | $1,776 |
| Ezetimibe | 71 | $1,106 |
| Carvedilol | 94 | $1,039 |
| Irbesartan | 22 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $328,811292 claims |
| Boehringer IngelheimJardiance | $403 | $91,24587 claims |
| Johnson & JohnsonXarelto | $318 | $90,42363 claims |
| NovartisEntresto | $231 | $39,36525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Colorado.
Other acute care in Boulder
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
- Rachele RobertsAurora$19K
- Shari Nieman CorsoLittleton$14K
- Lauren SpitzingerDenver$13K
- Gregory CharlestonPueblo$12K
- Shelley BuntingAurora$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.